Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects

Approximately 110 subjects will be enrolled and assigned to 1 of the 2 dose groups in a 1:1
ratio (55 subjects in each group). Subjects with a weight of at least 25 kg but less than 60
kg will receive a single IV dose of 1 g cefazolin. Subjects with a weight of at least 60 kg
will receive a single IV dose of 2 g cefazolin. Dose groups will not be balanced by age or
gender. Additional subjects may be enrolled if necessary to ensure at least 50 evaluable
subjects with complete safety data per dose group complete the study.

In a subset of approximately 40 subjects, 4 PK samples will be obtained to determine the
cefazolin plasma concentrations in this population.

Inclusion Criteria:

1. The subject is between the ages of 10 and 17 years (inclusive) at the time of giving
informed consent.

2. The subject is scheduled for surgery that will last less than 3 hours.

3. The subject and the subject's legally authorized representative voluntarily agree that
the subject will participate in this study. In accordance with applicable laws,
regulations, and institutional review board requirements, the subject signs or orally
agrees to an age-appropriate assent and the subject's legally authorized
representative signs both an institutional review board approved informed consent form
and Health Insurance Portability and Accountability Act authorization prior to the
performance of any screening procedures.

4. For subjects who agree to participate in the PK subgroup additional consent will be
obtained.

5. The subject weighs (on Day 1) ≥25 kg but <60 kg for inclusion in 1 g dose group.

6. The subject weighs (on Day 1) ≥60 kg for inclusion in 2 g dose group.

7. The subject has been scheduled for any type of surgery requiring single dose
perioperative cefazolin prophylaxis.

Exclusion Criteria:

1. Female subjects who are pregnant or lactating/breastfeeding.

2. Female subjects of childbearing potential who are sexually active and who are not
willing to use an effective method of birth control during the study period, eg, oral
contraceptives, double barrier methods, hormonal injectable or implanted
contraceptives, tubal ligation, or have a partner with a vasectomy.

3. The subject has impaired renal function based on the revised Schwartz formula.

4. The subject has a known allergy or hypersensitivity to β lactam/cephalosporin
antibiotics, penicillins, corn products, or dextrose containing products or solutions,
or any of the other ingredients of Cefazolin for Injection United States Pharmacopeia
(USP) and Dextrose Injection USP in DUPLEX.

5. The subject has abnormal vital signs or an abnormal electrocardiograph (ECG)
considered by the investigator to be clinically significant.

6. The subject has a result of any laboratory test (or repeat test, if done), obtained as
standard of care, that is outside the normal limit of the site's laboratory reference
range AND is considered by the investigator to be clinically significant.

7. The subject has a known history of human immunodeficiency virus, hepatitis B, or
hepatitis C infection.

8. The subject has a history of alcohol or drug abuse.

9. The subject has received any other investigational drug/device within 30 days prior to
the study drug administration.

10. The subject has a history of or is currently smoking or using nicotine-containing
substances or electronic cigarettes as determined by medical history or subject's
verbal report.